Search

Your search keyword '"Spiekerkoetter E"' showing total 68 results

Search Constraints

Start Over You searched for: Author "Spiekerkoetter E" Remove constraint Author: "Spiekerkoetter E" Database MEDLINE Remove constraint Database: MEDLINE
68 results on '"Spiekerkoetter E"'

Search Results

2. Somatic mutations in arteriovenous malformations in hereditary hemorrhagic telangiectasia support a bi-allelic two-hit mutation mechanism of pathogenesis.

3. Tricuspid annular plane systolic excursion in pulmonary hypertension-Moving beyond the sector plane.

4. 3D Imaging Reveals Complex Microvascular Remodeling in the Right Ventricle in Pulmonary Hypertension.

5. Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension-The Right Ventricle as a Therapeutic Target to Improve Renal Function.

6. MicroRNA-34a-Dependent Attenuation of Angiogenesis in Right Ventricular Failure.

7. Rat microbial biogeography and age-dependent lactic acid bacteria in healthy lungs.

8. Characterizing the Spatiotemporal Transcriptomic Response of the Right Ventricle to Acute Pressure Overload.

9. Rat microbial biogeography and age-dependent lactic acid bacteria in healthy lungs.

10. Repetitive schistosoma exposure causes perivascular lung fibrosis and persistent pulmonary hypertension.

11. Novel left ventricular mechanical index in pulmonary arterial hypertension.

12. The Human Respiratory Microbiome: Current Understandings and Future Directions.

13. The role of circular RNAs in pulmonary hypertension.

14. Relationship between impaired BMP signalling and clinical risk factors at early-stage vascular injury in the preterm infant.

15. Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT.

16. Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target.

17. Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency.

18. Improving Right Ventricular Function by Increasing BMP Signaling with FK506.

19. Arteriovenous Malformations-Current Understanding of the Pathogenesis with Implications for Treatment.

20. Promising therapeutic approaches in pulmonary arterial hypertension.

21. Role of Long Non-Coding RNAs in Pulmonary Arterial Hypertension.

22. Pulmonary arterial banding in mice may be a suitable model for studies on ventricular mechanics in pediatric pulmonary arterial hypertension.

23. Targeted proteomics of right heart adaptation to pulmonary arterial hypertension.

24. Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension.

25. Novel Advances in Modifying BMPR2 Signaling in PAH.

26. Repurposing of medications for pulmonary arterial hypertension.

27. A Notch3-Marked Subpopulation of Vascular Smooth Muscle Cells Is the Cell of Origin for Occlusive Pulmonary Vascular Lesions.

28. Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of pulmonary artery de-banding.

30. The hallmarks of severe pulmonary arterial hypertension: the cancer hypothesis-ten years later.

31. The left ventricle undergoes biomechanical and gene expression changes in response to increased right ventricular pressure overload.

32. Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure.

33. Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.

34. New and Emerging Therapies for Pulmonary Arterial Hypertension.

35. FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.

36. Drug repositioning in pulmonary arterial hypertension: challenges and opportunities.

37. A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.

38. Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension.

39. Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension.

40. Update in Pulmonary Vascular Disease 2016 and 2017.

41. Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association.

42. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension.

43. RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.

44. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

45. Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.

46. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors.

47. Targeting the Wnt signaling pathways in pulmonary arterial hypertension.

48. Current clinical management of pulmonary arterial hypertension.

49. Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.

50. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.

Catalog

Books, media, physical & digital resources